Reduction in pulmonary fibrosis in vivo by halofuginone

American Journal of Respiratory and Critical Care Medicine

Volumn 154, Issue 4 I, 1996, Pages 1082-1086

  Nagler, Arnon ^a   Firman, Natalie ^b   Feferman, Regina ^b   Cotev, Shamay ^b   Pines, Mark ^b   Shoshan, Shmuel ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; HALOFUGINONE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC LUNG DISEASE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MIXTURE; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029858861     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.154.4.8887611     Document Type: Article

References (35)

1. Krowka, M. J., E. C. Rosenow, and H. C. Hoagland. 1985. Pulmonary complications of bone marrow transplantation. Chest 87:237-246.
2. Breuer, R., I. S. Lossos, and G. E. Epler. 1992. Bone marrow transplantation: related pulmonary complications. Pulmon. Crit. Care Update 7:3-8.
3. Seiden, M. V., A. Elias, L. Ayash, M. Hunt, J. P. Eder, L. E. Schnipper, E. Frei, III, and K. H. Antman. 1992. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. Bone Marrow Transplant. 10:57-63.
4. Adamson, I. V. R., and D. H. Bowden. 1974. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am. J. Pathol. 77: 185-198.
5. Phan, S. H. 1995. New strategies for treatment of pulmonary fibrosis. Thorax 50:415-421.
6. Hunninghake, G. W., and A. R. Kalica. 1995. Approaches to the treatment of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 151: 915-918.
7. Snider, G. L., B. R. Celli, R. H. Goldstein, J. J. O'Brien, and E. G. Lucey. 1978. Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Am. Rev. Respir. Dis. 117:289-297.
8. Doherty, D. E., N. Hirose, L. Zagarella, and R. M. Cherniack. 1992. Prolonged monocyte accumulation in the lung during bleomycin-induced pulmonary fibrosis: a noninvasive assessment of monocyte kinetics by scintigraphy. Lab Invest. 66:231-242.
9. Hay, J. S., S. Shahzeidi, and G. Laurent. 1991. Mechanisms of bleomycin-induced lung damage. Arch. Toxicol. 65:81-94.
10. Goto, T., D. Befus, R. Low, and J. Bienenstock. 1984. Mast cell heterogeneity and hyperplasia in bleomycin-induced pulmonary fibrosis in rats. Am. Rev. Respir. Dis. 130:797-802.
11. Phan, S. H. 1989. Diffuse interstitial fibrosis. In D. Massaro, editor. Lung Cell Biology. Marcel Dekker, New York. 907-979.
12. Granot, I., I. Bartov, I. Plavnik, E. Wax, S. Hurwitz, and M. Pines. 1991. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poult. Sci. 70:1559-1563.
13. Levi-Schaffer, F., A. Nagler, S. Slavin, V. Knopov, and M. Pines. 1995. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. J. Invest. Dermatol. 106:84-88.
14. Choi, E. T., A. D. Callow, N. L. Sehgal, D. M. Brown, and U. S. Ryan. 1995. Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intima hyperplasia. Arch. Surg. 130:257-261.
15. Granot, I., S. Hurwitz, O. Halevy, and M. Pines. 1993. Halofuginone: an inhibitor of collagen type I synthesis. Biochim. Biophys. Acta 1156:107-112.
16. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt. Biochem. 72:248-254.
17. Stegemann, H., and K. Stalder. 1967. Determination of hydroxyproline. Clin. Chim. Acta 18:267-273.
18. Burton, K. 1968. Determination of DNA concentration with diphenylamine. Meth. Enzymol. XII-B:163-166.
19. Marani, A. 1972. Methods of Planning and Conduction of Experiments. Academon Press, Jerusalem. 33.
20. Tetlow, L. C., and D. E. Woolley. 1995. Distribution, activation and tryptase/chymase phenotype of mast cells in the rheumatoid lesion. Ann. Rheum. Dis. 54:549-555.
21. Shoshan, S., and J. Gross. 1974. The biosynthesis and metabolism of collagen and its role in tissue repair processes. Isr. J. Med. Sci. 10:537-568.
22. Shoshan, S. 1981. Wound healing. Int. Rev. Conn. Tissue Res. 9:1-26.
23. Shoshan S., B. Saks, A. Shifter, and S. Pisanti. 1990. The effect of β-receptor blocking agent, Cyclosporin A, and calcium antagonist (Nifedipin) on collagen production in granulation tissue in vivo. Ann. N. Y. Acad. Sci. 580:570-572.
24. Umezawa, H., M. Ishizuka, K. Maeda, and T. Takeuchi. 1967. Studies on bleomycin. Cancer 20:891-895.
25. Otsuka, K., S. Murota, and Y. Mori. 1976. Stimulatory effect ot bleomycin on the synthesis of acidic glycosaminoglycans in cultured fibroblasts derived from rat carrageenin granuloma. Biochim. Biophys. Acta 444:359-368.
26. Clark, J. G., B. C. Starcher, and J. Uitto. 1980. Bleomycin-induced synthesis of type I procollagen by human lung and skin fibroblasts in culture. Biochim. Biophys. Acta 631:359-370.
27. Zhang, K., M. Gharaee-Kermani, M. L. Jones, J. S. Warren, and S. H. Phan. 1994. Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. J. Immunol. 153:4733-4741.
28. V mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cell, on fibrosis. Int. Arch. Allergy Appl. Immunol. 95:195-201.
29. Botana, L. M., E. Arnaez, M. R. Vicytes, A. Alfonso, and M. C. Louzao. 1992. Nonimmunological release of histamine from rat mast cells elicited by antineoplastic agents: effect of drug combinations. Cancer Chemother. Pharmacol. 30:487-490.
30. Cross, C. E., D. Warren, J. E. Gerriets, D. W. Wilson, B. Halliwel, and J. A. Last. 1985. Deferroxamine injection does not affect bleomycin-induced lung fibrosis in rats. J. Lab. Clin. Med. 106:433-438.
31. Sendelbach, L. E., R. C. Lindenschmidt, and H. P. Witschi. 1985. The effect of Cyclosporin A on pulmonary fibrosis induced by butylated hydroxytoluene, bleomycin and beryllium sulfate. Toxicol. Lett. 26: 163-173.
32. Nagai, A., K. Aoshiba, Y. Ishihara, H. Inano, K. Sakamoto, and E. Yamaguchi. 1992. Administration of α1-proteinase inhibitor ameliorates bleomycin-induced pulmonary fibrosis in hamsters. Am. Rev. Respir. Dis. 145:651-656.
33. Piguet, P. F., M. A. Collart, G. E. Grau, Y. Kapanci, and P. Vassali. 1989. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med. 170:655-663.
34. Raghow, R., P. Irish, and A. H. Kang. 1989. Coordinate regulation of transforming growth factor β gene expression and cell proliferation in hamster lungs undergoing bleomycin-induced pulmonary fibrosis. J. Clin. Invest. 84:1836-1842.
35. Giri, S. N., and D. M. Hyde. 1988. Ameliorating effect of an interferon inducer polyinosinic-polycytidylic acid on bleomycin-induced lung fibrosis in hamsters. Morphologic and biochemical evidence. Am. J. Pathol. 133:525-536.